CoChat

Prognostic value of TP53,KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort

Open access
Scoccianti, Chiara, Vesin, Aurélien, Martel, Ghislaine, Olivier, Magali, Brambilla, Elisabeth, Timsit, Jean-François, Tavecchio, Luca, Brambilla, Christian, Field, John K., Hainaut, Pierre, the European Early Lung Cancer Consortium · 2012 · European Respiratory Journal
Cited by 115

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Nonsmall cell lung cancer samples from the European Early Lung Cancer biobank were analysed to assess the prognostic significance of mutations in the TP53,KRAS and EGFR genes. The series included 11 never-smokers, 86 former smokers, 152 current smokers and one patient without informed smoking status. There were 110 squamous cell carcinomas (SCCs), 133 adenocarcinomas (ADCs) and seven large cell carcinomas or mixed histologies. Expression of p53 was analysed by immunohistochemistry. DNA was extracted from frozen tumour tissues. TP53 mutations were detected in 48.8% of cases and were more frequent among SCCs than ADCs (p<0.0001).TP53 mutation status was not associated with prognosis. G to T transversions, known to be associated with smoking, were marginally more common among patients who developed a second primary lung cancer or recurrence/metastasis (progressive disease).EGFR mutations were almost exclusively found in never-smoking females (p=0.0067).KRAS mutations were detected in 18.5% of cases, mainly ADC (p<0.0001), and showed a tendency toward association with progressive disease status. These results suggest that mutations are good markers of different aetiologies and histopathological forms of lung cancers but have little prognostic value, with the exception of KRAS mutation, which may have a prognostic value in ADC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.00097311

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 115

Metadata

Authors
Scoccianti, C., Vesin, A., Martel, G., Olivier, M., Brambilla, E., Timsit, J.-F., Tavecchio, L., Brambilla, C., Field, J. K., Hainaut, P., & the European Early Lung Cancer Consortium
Venue
European Respiratory Journal
Published
2012-01-20
Volume
40
Issue
1
Pages
177-184
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2104811705
Cited by
115
References
6
FWCI
7.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic value of TP53,KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. https://app.cochat.ai/papers/10.1183/09031936.00097311
The paper
Scoccianti, C., Vesin, A., Martel, G., Olivier, M., Brambilla, E., Timsit, J.-F., Tavecchio, L., Brambilla, C., Field, J. K., Hainaut, P., & the European Early Lung Cancer Consortium. (2012). Prognostic value of TP53,KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. European Respiratory Journal. https://doi.org/10.1183/09031936.00097311

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.